Colorectal adenomas and MAFLD: a cross-sectional study in a Hispanic screening cohort

Abstract

Aims: Prior evidence demonstrates an association between non-alcoholic fatty liver disease (NAFLD) and colorectal adenomas (CRA) risk. However, information using the new definition of the disease [i.e., metabolic dysfunction-associated fatty liver disease (MAFLD)] is scarce. We aimed to assess the relationship between MAFLD and CRA risk.

Methods: We conducted a cross-sectional study including patients from three university centers in Chile who underwent a colonoscopy for colorectal cancer screening and abdominal imaging study. We obtained sociodemographic and clinical data, and we performed univariate and multivariable regression analyses.

Results: In total, 895 patients were included; 42% were male, the mean age was 59.9 ± 9.3 years, and 37.8% (338) had CRA. Patients harboring polyps were predominantly males (48.2% vs. 38.2%, P = 0.002), older (61.6 ± 8.7 years vs. 58.9 ± 9.5 years, P < 0.001), and exhibited a higher body weight than controls [75 (66-88) kg vs. 72 (63-82.3) kg, P = 0.002]. Fifty-six percent of patients showed hepatic steatosis in imaging studies and 54.4% met MAFLD diagnostic criteria. The adenoma detection rate was higher in the MAFLD group compared to controls (46.4% vs. 27.5%, P < 0.001). In the multivariable analysis, MAFLD was significantly associated with the presence of CRA (odds ratio = 2.32; 95%CI: 1.68-3.19, P < 0.0001). There were no statistically significant differences of histopathological characteristics of the adenomas according to the presence of MAFLD.

Conclusion: The present study shows that, in Chilean Hispanic subjects, MAFLD is associated with an increased risk of CRA. This information may be useful to design specific screening colonoscopy recommendations in MAFLD patients.

Keywords

MAFLD / colorectal adenoma / steatosis / adenoma detection rate / steatosis / steatohepatitis / fatty liver

References

[1] Bray F,Soerjomataram I,Torre LA.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2018;68:394-424

[2] Sierra MS.Burden of colorectal cancer in Central and South America.Cancer Epidemiol2016;44 Suppl 1:S74-81

[3] Ríos JA,Arce MJ.[The present situation of colorectal cancer in Chile].Rev Med Chil2020;148:858-67

[4] Leslie A,Pratt NR.The colorectal adenoma-carcinoma sequence.Br J Surg2002;89:845-60

[5] Carballal S,Balaguer F.Serrated polyps and serrated polyposis syndrome.Cir Esp2013;91:141-8

[6] Shussman N.Colorectal polyps and polyposis syndromes.Gastroenterol Rep (Oxf)2014;2:1-15 PMCID:PMC3920990

[7] Mangas-sanjuan C,Cubiella J.Endoscopic surveillance after colonic polyps and colorrectal cancer resection. 2018 update.Gastroenterol Hepatol (English Edition)2019;42:188-201

[8] Dekker E,Vleugels JLA,Wallace MB.Colorectal cancer.Lancet2019;394:1467-80

[9] Nishihara R,Lochhead P.Long-term colorectal-cancer incidence and mortality after lower endoscopy.N Engl J Med2013;369:1095-105 PMCID:PMC3840160

[10] Mandel JS,Ederer F.Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood.J Natl Cancer Inst1999;91:434-7

[11] Shaukat A,Burke CA,Sauer BG.ACG Clinical Guidelines: colorectal cancer screening 2021.Am J Gastroenterol2021;116:458-79

[12] Rex DK,Cohen J.Quality indicators for colonoscopy.Am J Gastroenterol2015;110:72-90

[13] Younossi Z,Arrese M.Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.Hepatology2019;69:2672-82

[14] Kim GA,Choe J.Association between non-alcoholic fatty liver disease and cancer incidence rate.J Hepatol2017;S0168-8278(17)32294-8:

[15] Chen W,Jing X.High risk of colorectal polyps in men with non-alcoholic fatty liver disease: a systematic review and meta-analysis.J Gastroenterol Hepatol2020;35:2051-65

[16] Blackett JW,Lebwohl B.Increased prevalence of colorectal adenomas in patients with nonalcoholic fatty liver disease: a cross-sectional study.Dig Dis2020;38:222-30

[17] Eslam M,George J.International Consensus PanelMAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease.Gastroenterology2020;158:1999-2014.e1

[18] Fouad Y,Bollipo S,Ajlouni Y.What's in a name?.Liver Int2020;40:1254-61

[19] Dulai PS,Gupta S.Colorectal cancer and dysplasia in inflammatory bowel disease: a review of disease epidemiology, pathophysiology, and management.Cancer Prev Res (Phila)2016;9:887-94 PMCID:PMC5289746

[20] Lai EJ,Doros G,Jacobson BC.The Boston bowel preparation scale: a valid and reliable instrument for colonoscopy-oriented research.Gastrointest Endosc2009;69:620-5 PMCID:PMC2763922

[21] Johnson CM,Ensor JE.Meta-analyses of colorectal cancer risk factors.Cancer Causes Control2013;24:1207-22 PMCID:PMC4161278

[22] Dong Y,Shu Y.Link between risk of colorectal cancer and serum vitamin E levels: a meta-analysis of case-control studies.Medicine (Baltimore)2017;96:e7470 PMCID:PMC5502190

[23] Kobiela J,Jędrusik P.Metformin and colorectal cancer - a systematic review.Exp Clin Endocrinol Diabetes2019;127:445-54

[24] Dobrzycka M,Łachiński AJ,Jędrusik P.Statins and colorectal cancer - a systematic review.Exp Clin Endocrinol Diabetes2020;128:255-62

[25] Guo CG,Drew DA.Aspirin use and risk of colorectal cancer among older adults.JAMA Oncol2021;7:428-35 PMCID:PMC7821085

[26] Lee S,Kim JW.Obstructive sleep apnea is associated with an increased risk of colorectal neoplasia.Gastrointest Endosc2017;85:568-73.e1

[27] Niederseer D,Huber-Schönauer U.Cardiovascular risk and known coronary artery disease are associated with colorectal adenoma and advanced neoplasia.J Am Coll Cardiol2017;69:2348-50

[28] Lasa J,Bracho LF.Colorectal adenoma risk is increased among recently diagnosed adult celiac disease patients.Gastroenterol Res Pract2018;2018:6150145 PMCID:PMC5937376

[29] Eslam M,Sarin SK.A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement.J Hepatol2020;73:202-9

[30] Hydes T,Hamid A,Cuthbertson DJ.Current and emerging biomarkers and imaging modalities for nonalcoholic fatty liver disease: clinical and research applications.Clin Ther2021;43:1505-22

[31] Hidalgo B.Multivariate or multivariable regression?.Am J Public Health2013;103:39-40 PMCID:PMC3518362

[32] Seo JY,Kwak MS.The risk of colorectal adenoma in nonalcoholic or metabolic-associated fatty liver disease.Biomedicines2021;9:1401 PMCID:PMC8533199

[33] Thune I,Thompson RL,Mitrou PN.Abstract P3-10-06: what is the latest evidence on diet, nutrition, physical activity and cancer - key findings from the WCRF/AICR continuous update project.Cancer Res2018;78

[34] Chen X,Song Q,Cao D.Insulin promotes progression of colon cancer by upregulation of ACAT1.Lipids Health Dis2018;17:122 PMCID:PMC5968618

[35] Aslan A,Celik MA,Cankaya S.Investigation of insulin-like growth factor-1 (IGF-1), P53, and Wilms' tumor 1 (WT1) expression levels in the colon polyp subtypes in colon cancer.Med Sci Monit2019;25:5510-7 PMCID:PMC6676992

[36] Scherübl H.Excess body weight and gastrointestinal cancer risk.Visc Med2021;37:261-6 PMCID:PMC8406359

[37] Mili N,Goulis DG,Lambrinoudaki I.Obesity, metabolic syndrome, and cancer: pathophysiological and therapeutic associations.Endocrine2021;74:478-97

[38] Hwang ST,Park JH.Relationship of non-alcoholic fatty liver disease to colorectal adenomatous polyps.J Gastroenterol Hepatol2010;25:562-7

[39] Chen QF,Sun YJ.Sex-influenced association of non-alcoholic fatty liver disease with colorectal adenomatous and hyperplastic polyps.World J Gastroenterol2017;23:5206-15 PMCID:PMC5537187

[40] Chen J,Zang S.The association between nonalcoholic fatty liver disease and risk of colorectal adenoma and cancer incident and recurrence: a meta-analysis of observational studies.Expert Rev Gastroenterol Hepatol2019;13:385-95

[41] Araújo AR,Bedogni G,Bellentani S.Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: what we need in the future.Liver Int2018;38 Suppl 1:47-51

[42] López-Kostner F,Ponce A.[Results of a multicentric colorectal cancer screening program in Chile].Rev Med Chil2018;146:685-92

[43] Chakraborty D.Nonalcoholic fatty liver disease and colorectal cancer: correlation and missing links.Life Sci2020;262:118507 PMCID:PMC8128156

[44] Gadaleta RM,Moschetta A.Bile acids and colon cancer: is FXR the solution of the conundrum?.Mol Aspects Med2017;56:66-74

[45] Degirolamo C,Palasciano G.Bile acids and colon cancer: solving the puzzle with nuclear receptors.Trends Mol Med2011;17:564-72

[46] Arab JP,Dawson PA,Trauner M.Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives.Hepatology2017;65:350-62 PMCID:PMC5191969

[47] Kim ER.Colorectal cancer in inflammatory bowel disease: the risk, pathogenesis, prevention and diagnosis.World J Gastroenterol2014;20:9872-81 PMCID:PMC4123369